Genetic program activity delineates risk, relapse, and therapy responsiveness in Multiple Myeloma
Matthew A. Wall, Serdar Turkarslan, Wei‐Ju Wu, Samuel A. Danziger, David J. Reiss, Mike J. Mason, Andrew Dervan, Matthew W. B. Trotter, Douglas E. Bassett, Robert Mark Hershberg, Adrián López García de Lomana, Alexander V. Ratushny, Nitin S. Baliga
The paper identifies 141 genetic programs in multiple myeloma that predict disease outcomes and reveal mechanisms of relapse and therapy response.
npj Precision Oncology · Jun 28, 2021Peer-reviewedSystems Biology